Literature DB >> 1678273

Renal and neurohumoral effects of ibopamine and metoclopramide in normal man.

A R Girbes1, D J van Veldhuisen, A J Smit, A Drent-Bremer, S Meijer, W D Reitsma.   

Abstract

The effects of 100 mg ibopamine, an orally active nonselective dopamine agonist on renal haemodynamics, sodium excretion, blood pressure (BP), heart rate (HR) and neurohumoral parameters were investigated in 10 healthy volunteers, with and without metoclopramide pretreatment. A small and temporary rise of glomerular filtration rate (GFR) was found after ibopamine without but not with metoclopramide pretreatment. No differences in effective renal plasma flow (ERPF) but a small rise in sodium excretion were observed comparing ibopamine with control. Metoclopramide induced a fall in sodium excretion which was not reversed by ibopamine. Ibopamine failed to affect BP and HR and no changes of PRA or plasma aldosterone concentration (PAC) were found. Metoclopramide induced a pronounced increase of PAC which was blunted by ibopamine. Plasma and urinary catecholamines were unchanged for all study days. We conclude that ibopamine induces natriuresis probably not by the observed small and temporary renal haemodynamic effects but by direct stimulation of DA1 dopamine receptors in the proximal tubule.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678273      PMCID: PMC1368584          DOI: 10.1111/j.1365-2125.1991.tb05597.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow.

Authors:  A J Donker; G K van der Hem; W J Sluiter; H Beekhuis
Journal:  Neth J Med       Date:  1977       Impact factor: 1.422

2.  Lack of effect of ibopamine, a dopamine pro-drug, on renal function in normal subjects.

Authors:  J N Harvey; D P Worth; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

3.  Renal effect of SB 7505: a double-blind study.

Authors:  G F Melloni; G M Minoja; G Scorazzati; R Bauer; B Brusoni; P Ghirardi
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

4.  Total and intrarenal flow distribution in healthy subjects: technique, acute effects of ibopamine and of indoramin.

Authors:  K E Britton; M K Nawaz; C C Nimmon; E Mlodkowska; M Carroll; T Horne; M Granowska
Journal:  Nephron       Date:  1986       Impact factor: 2.847

5.  Cardiovascular characterization of DA-1 and DA-2 dopamine receptor agonists in anesthetized rats.

Authors:  I Cavero; C Thiry; J Pratz; K Lawson
Journal:  Clin Exp Hypertens A       Date:  1987

6.  Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.

Authors:  S I Rajfer; J D Rossen; F L Douglas; L I Goldberg; T Karrison
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

7.  Tonic dopaminergic suppression of plasma aldosterone.

Authors:  R H Noth; R W McCallum; C Contino; J Havelick
Journal:  J Clin Endocrinol Metab       Date:  1980-07       Impact factor: 5.958

8.  Ibopamine (SB 7505) in normal subjects and in chronic renal failure: a preliminary report.

Authors:  S Stefoni; L Colì; G Mosconi; R Prandini
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

9.  Dopamine receptors in the proximal tubule of the rabbit.

Authors:  R A Felder; M Blecher; P L Calcagno; P A Jose
Journal:  Am J Physiol       Date:  1984-09

10.  Dopaminergic blockade of the renin-angiotensin-aldosterone system: effect of high and low sodium intakes.

Authors:  M B Gordon; T J Moore; R G Dluhy; G H Williams
Journal:  Clin Endocrinol (Oxf)       Date:  1983-10       Impact factor: 3.478

View more
  1 in total

Review 1.  Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.

Authors:  C Spencer; D Faulds; A Fitton
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.